{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:40Z","timestamp":1790612200252,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR10855\/BRB\/10\/1330\/2014"],"award-info":[{"award-number":["BT\/PR10855\/BRB\/10\/1330\/2014"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jprot.2019.103504","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T11:36:13Z","timestamp":1566819373000},"page":"103504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach"],"prefix":"10.1016","volume":"209","author":[{"given":"Venkatesh","family":"Chanukuppa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushman","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tathagata","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeevan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas K.","family":"Santra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0273-0819","authenticated-orcid":false,"given":"Srikanth","family":"Rapole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jprot.2019.103504_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/sonc.2002.34074","article-title":"High-dose therapy and immunomodulatory drugs in multiple myeloma","author":"Barlogie","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jprot.2019.103504_bb0015","series-title":"Mayo Clinic Proceedings","first-page":"1371","article-title":"Multiple myeloma: diagnosis and treatment","author":"Rajkumar","year":"2005"},{"issue":"20","key":"10.1016\/j.jprot.2019.103504_bb0020","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone (s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jprot.2019.103504_bb0025","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.jprot.2019.103504_bb0030","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jprot.2019.103504_bb0035","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jprot.2019.103504_bb0040","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jprot.2019.103504_bb0045","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jprot.2019.103504_bb0050","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"Bench-to-bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0055","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jprot.2019.103504_bb0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"46","key":"10.1016\/j.jprot.2019.103504_bb0070","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11340","article-title":"Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors","volume":"7","author":"Franke","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jprot.2019.103504_bb0075","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nrm3461","article-title":"Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions","volume":"13","author":"Raices","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrc3219","article-title":"The nuclear envelope environment and its cancer connections","volume":"12","author":"Chow","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.jprot.2019.103504_bb0085","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ijc.24146","article-title":"The Karyopherin proteins, Crm1 and Karyopherin \u03b21, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation","volume":"124","author":"Van der Watt","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0090","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/emboj\/18.6.1660","article-title":"A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking","volume":"18","author":"Stommel","year":"1999","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(02)01255-2","article-title":"Parc: a cytoplasmic anchor for p53","volume":"112","author":"Nikolaev","year":"2003","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jprot.2019.103504_bb0100","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.23354","article-title":"Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer","volume":"112","author":"Noske","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1631\/jzus.2006.B0411","article-title":"Proteomic technology for biomarker profiling in cancer: an update","volume":"7","author":"Alaoui-Jamali","year":"2006","journal-title":"J Zhejiang Univ Sci B"},{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.celrep.2013.07.018","article-title":"Global proteome analysis of the NCI-60 cell line panel","volume":"4","author":"Gholami","year":"2013","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.jprot.2019.103504_bb0115","first-page":"1987","article-title":"A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF-7 breast cancer cells","volume":"42","author":"Sommer","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jprot.2019.103504_bb0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jprot.2016.02.008","article-title":"Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma","volume":"138","author":"Paul","year":"2016","journal-title":"J. Proteome"},{"issue":"4","key":"10.1016\/j.jprot.2019.103504_bb0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1989.306","article-title":"The MTT assay underestimates the growth inhibitory effects of interferons","volume":"60","author":"Jabbar","year":"1989","journal-title":"Br. J. Cancer"},{"issue":"7247","key":"10.1016\/j.jprot.2019.103504_bb0130","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nature08011","article-title":"F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage","volume":"459","author":"Santra","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00007890-196411000-00001","article-title":"Evaluation of the trypan blue technique for determination of cell viability","volume":"2","author":"Tennant","year":"1964","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.jprot.2019.103504_bb0140","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.1977.239","article-title":"Clonogenic assays in the B16 melanoma: response to cyclophosphamide","volume":"36","author":"Steel","year":"1977","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/13816128113199990611","article-title":"Understanding XPO1 target networks using systems biology and mathematical modeling","volume":"20","author":"Muqbil","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"77","key":"10.1016\/j.jprot.2019.103504_bb0155","doi-asserted-by":"crossref","first-page":"34567","DOI":"10.18632\/oncotarget.26179","article-title":"XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies","volume":"9","author":"Baek","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jprot.2019.103504_bb0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear\u2013cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.jprot.2019.103504_bb0165","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","article-title":"XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy","volume":"10","author":"Camus","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.25011\/cim.v32i6.10668","article-title":"Prognostic value of CRM1in pancreas cancer","volume":"32","author":"Huang","year":"2009","journal-title":"Clin. Investig. Med."},{"issue":"11","key":"10.1016\/j.jprot.2019.103504_bb0180","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1002\/ajh.24496","article-title":"Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia","volume":"91","author":"Jain","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"7623","key":"10.1016\/j.jprot.2019.103504_bb0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature19771","article-title":"XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer","volume":"538","author":"Kim","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-016-0338-2","article-title":"CRM1\/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways","volume":"9","author":"Liu","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0195","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.jprot.2019.103504_bb0205","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp. hematol. & oncol."},{"issue":"6","key":"10.1016\/j.jprot.2019.103504_bb0215","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","article-title":"Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer","volume":"23","author":"Chen","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jprot.2019.103504_bb0220","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/cancers11040479","article-title":"Combined targeting of Estrogen receptor alpha and XPO1 prevent Akt activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance","volume":"11","author":"Kulkoyluoglu-Cotul","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.22913","article-title":"SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties","volume":"58","author":"Yadav","year":"2019","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-017-3908-y","article-title":"RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation","volume":"18","author":"Wu","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/cancers8030035","article-title":"Mechanisms of nuclear export in cancer and resistance to chemotherapy","volume":"8","author":"El-Tanani","year":"2016","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jprot.2019.103504_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022423","article-title":"Silencing nuclear pore protein Tpr elicits a senescent-like phenotype in cancer cells","volume":"6","author":"David-Watine","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-18-1","article-title":"Induction of HSPA4 and HSPA14 by NBS1 overexpression contributes to NBS1-induced in vitro metastatic and transformation activity","volume":"18","author":"Wu","year":"2011","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.jprot.2019.103504_bb0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1535-7163.MCT-04-0241","article-title":"Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells","volume":"4","author":"Atienza","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0255","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/j.1460-2075.1991.tb07929.x","article-title":"The MYC protein activates transcription of the alpha-prothymosin gene","volume":"10","author":"Eilers","year":"1991","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(92)90123-T","article-title":"Induction of apoptosis in fibroblasts by c-myc protein","volume":"69","author":"Evan","year":"1992","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jprot.2019.103504_bb0270","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0959-437X(05)80339-9","article-title":"The role of c-myc in cell growth","volume":"3","author":"Evan","year":"1993","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"16","key":"10.1016\/j.jprot.2019.103504_bb0275","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.4161\/cc.21476","article-title":"E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73\/DNp73-miR-205 circuitry","volume":"11","author":"Alla","year":"2012","journal-title":"Cell Cycle"},{"issue":"D1","key":"10.1016\/j.jprot.2019.103504_bb0280","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","article-title":"2016 update of the PRIDE database and its related tools","volume":"44","author":"Vizca\u00edno","year":"2015","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391919302763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391919302763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:55:48Z","timestamp":1777622148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391919302763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":56,"alternative-id":["S1874391919302763"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2019.103504","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2019.103504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103504"}}